Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Curis Lifesciences Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Curis Lifesciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Curis Lifesciences - Trading Window
-
Curis Lifesciences Ltd. debuts with 14.14% premium at Rs 146.10
-
Curis Lifesciences announces launch of initial public offering
Key fundamentals
Evaluate the intrinsic value of Curis Lifesciences Ltd stock
| Name | March-25 | March-24 | |||
|---|---|---|---|---|---|
| Assets | 31.8451 | 22.9618 | |||
| Liabilities | 31.8451 | 22.9618 | |||
| Equity | 5.9344 | 0.5 | |||
| Gross Profit | 9.5373 | 8.3876 | |||
| Net Profit | 6.1051 | 4.867 | |||
| Cash From Operating Activities | -1.7625 | 0.28 | |||
| NPM(%) | 12.42 | 13.68 | |||
| Revenue | 49.1323 | 35.5557 | |||
| Expenses | 39.595 | 27.1681 | |||
| ROE(%) | 28.73 | 22.9 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Curis Lifesciences Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 780.40 | -0.84 | 0.00 | 0.00 | 301.39 | 0.64 |
| Lotus Eye Hospital and Institute Ltd | 105.00 | -0.57 | 328.13 | 0.00 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 9.11 | -3.80 | 0.00 | 0.00 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 890.00 | 7.36 | 0.00 | 0.00 | -604.77 | 0.00 |
Company Info
Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd, 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.
Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd, 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.
Read More
Parent Organisation
Curis Lifesciences Ltd.
Founded
23/03/2016
Managing Director
Mr.Dharmesh Dasharathbhai Patel
NSE Symbol
CURISST
FAQ
The current price of Curis Lifesciences Ltd is
The 52-week high for Curis Lifesciences Ltd is
The market capitalization of Curis Lifesciences Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Curis Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Curis Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Curis Lifesciences Ltd shares.
The CEO of Curis Lifesciences Ltd is Mr.Dharmesh Dasharathbhai Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.